Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4001 to 4050 of 4091 results for patient

  1. Three treatments for COVID-19 recommended in final draft guidance

    Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.

  2. Starting with the end in mind - the Innovative Licensing and Access Pathway

    The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.

  3. Peripheral arterial disease: antiplatelets (IND94)

    This indicator covers the percentage of patients with peripheral arterial disease with a record in the preceding 15 months that aspirin or an alternative antiplatelet is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM33

  4. Bipolar, schizophrenia and other psychoses: annual blood pressure (IND84)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM17

  5. Bipolar, schizophrenia and other psychoses: annual BMI recording (IND83)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM16

  6. Bipolar, schizophrenia and other psychoses: annual record of alcohol consumption (IND82)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomesThis indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM15

  7. Diabetes: annual foot exam and risk classification (IND81)

    This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13

  8. Smoking: smoking status for people with long-term conditions (IND97)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38

  9. Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE

    Improved deal signals NICE recommendation of sickle cell treatment voxelotor.

  10. Hypertension: confirming diagnosis with HBPM or ABPM (IND115)

    This indicator covers the percentage of patients with a new diagnosis of hypertension (diagnosed on or after 1 April 2014) which has been confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) in the 3 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM66

  11. Dementia: named carer (IND114)

    This indicator covers the percentage of patients with dementia with the contact details of a named carer on their record. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM64

  12. Hypertension: haematuria for target organ damage (IND122)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a test for haematuria in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM76

  13. Learning disabilities: register (IND119)

    This indicator covers establishing and maintaining a register of patients with learning disabilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM73

  14. Weight management: advice for people living with overweight (18 to 39 years) (IND319)

    This indicator covers the percentage of patients aged 18 to 39 years with a BMI of 23 kg/m2 to 27.4 kg/m2 (or 25 kg/m2 to 29.9 kg/m2 if ethnicity is recorded as White) in the preceding 12 months who have been given weight management advice within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  15. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator covers the percentage of patients on the CKD register and currently treated with an angiotensin receptor blocker (ARB) or an ACE inhibitor (unless these are contraindicated) who are also treated with an SGLT-2 inhibitor if they have: no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2, or no type 2 diabetes and an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2 and a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more, or type 2 diabetes and a urine ACR 3 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  16. Heart failure: 4 pillars (HFrEF) (IND317)

    This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  17. Around 100,000 fewer colonoscopies expected to take place each year

    Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.

  18. New treatment option recommended for people with type 2 diabetes

    Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.

  19. Digital services to enable easier access to weight management support

    Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England

  20. Speaking with one language: How using a common data model might speed up decision making

    The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.

  21. New treatment option for adults with obesity and non-diabetic hyperglycaemia

    All eligibility criteria must be met for Liraglutide to be offered.

  22. Statins a choice for more people to reduce risk of heart attacks and strokes

    New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.

  23. New NICE quality standard identifies improvements in UTI diagnosis for women

    Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms.

  24. Nine treatment options to be made available for adults with depression or an anxiety disorder

    Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS.

  25. Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund

    NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.

  26. Supporting the NHS's ambition for virtual wards

    An early introduction to NICE’s ongoing activity in virtual wards

  27. How 'surrogate outcomes' influence long-term health outcomes

    NICE working with international organisations to develop guidance.

  28. Testing could help prevent further strokes in people with gene variant

    People who have had an ischaemic stroke or transient ischaemic attack should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes

  29. £1.8m funding awarded to explore guidance on regulating digital mental health tools

    NICE and the MHRA have been awarded £1.8m funding by Wellcome over three years to explore and produce guidance on regulating digital mental health tools.

  30. NICE recommends a weekly injection for treating growth failure in children

    This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.

  31. How NICE is ensuring its topic prioritisation decisions are grounded in lived experience

    Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.

  32. NICE collaboration on streamlined licensing and patient access process for new medicines

    Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.

  33. How NICE manages the potential conflicts of interests of patient experts

    People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.

  34. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.

  35. Emergency kits for people with adrenal insufficiency recommended to avoid hospital admission

    People with adrenal insufficiency should be given an emergency medical kit with potentially life-saving steroid injections, according to our new clinical guideline.

  36. Listening to patients and organisations to update NICE's quality standard on transition from children's to adults' services

    Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.

  37. New clot-busting drug recommended by NICE set to save NHS £millions

    Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.

  38. NICE recommends digital technology to help diagnose ADHD in children and young people

    A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.

  39. NICE recommended a new gene therapy, transformative cystic fibrosis medicines and an obesity jab, during election period

    More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.

  40. New tests could spare people with early breast cancer from unnecessary chemotherapy

    More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.

  41. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  42. NICE launches refreshed support service for life sciences industry

    NICE has launched its refreshed support service for the life sciences sector, NICE Advice.

  43. Learn more about NICE's new guideline on identifying and managing adrenal insufficiency

    Hospital, to discuss the guideline and the benefits it will provide to patients and healthcare professionals. Other ways to listen Our...

  44. NICE collaborates with international partner agencies to streamline the confidential marking process

    NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.

  45. 145,000 people in England to have further treatment choice for preventing migraine attacks

    NICE has for the first time recommended an oral treatment for preventing migraines.

  46. NICE recommends olaparib for early breast cancer and metastatic prostate cancer

    Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.

  47. NICE recommends genetic test to prevent newborn babies going deaf

    A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.

  48. New treatment option available for womb cancer

    A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.

  49. NICE publishes final draft guidance on Enhertu after commercial discussions conclude

    NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  50. 25,000 people to benefit after NICE recommends new ulcerative colitis treatment

    New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.